Johnson & Johnson Innovation

Plus: Updates from Enara, Paq, Priothera, Eccogene

Total CDER approvals stand at 10 so far this year, 50% less than at this time last year

Plus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more

On BioCentury’s latest podcast: Why tau may be approaching a tipping point for Alzheimer’s drug development

German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition

An advancing wave of new candidates, spanning diverse modalities, converges with push for surrogate endpoint status

Plus: Changes at Halda, Calidi, Creyon, Aurion, Protalix, Theradaptive and Boston Scientific

Plus: Roivant takes greater oversight role at Immunovant, installs new CEO; and more

BioCentury’s Management Roundup also includes updates from Galapagos, Proqr, GC, Gates MRI, Viatris and AB Sciex

To avoid sweeping tariffs, pharmas announce U.S. manufacturing investments, warn of generics shortages